Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castration-resistant Prostate Cancer”

1,154 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,154 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06004661
What this trial is testing

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 23
Not applicableLooking for participantsNCT06600802
What this trial is testing

Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer

Who this might be right for
Castration-resistant Metastatic Prostate CancerTreated by 177Lutetium-PSMA-617 (Lu-PSMA)
Centre Jean Perrin 120
Not applicableStudy completedNCT03223727
What this trial is testing

Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223

Who this might be right for
Prostate Cancer MetastaticBone Metastases
The Netherlands Cancer Institute 100
Early research (Phase 1)Looking for participantsNCT07316686
What this trial is testing

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

Who this might be right for
Prostate Cancer (Adenocarcinoma)
Instituto do Cancer do Estado de São Paulo 18
Early research (Phase 1)Looking for participantsNCT06062745
What this trial is testing

Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT

Who this might be right for
Advanced Prostate CancerMetastatic Prostate CancerMetastatic Prostate Neuroendocrine Carcinoma
Brigham and Women's Hospital 30
Large-scale testing (Phase 3)Ended earlyNCT03850795
What this trial is testing

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer MetastaticCastration-resistant Prostate Cancer
Hinova Pharmaceuticals USA, Inc. 104
Testing effectiveness (Phase 2)Looking for participantsNCT05413850
What this trial is testing

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancermCRPC+3 more
Blue Earth Therapeutics Ltd 82
Testing effectiveness (Phase 2)Study completedNCT02047253
What this trial is testing

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
University of Alabama at Birmingham 28
Early research (Phase 1)Looking for participantsNCT07621692
What this trial is testing

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
National Taiwan University Hospital 12
Testing effectiveness (Phase 2)UnknownNCT04486937
What this trial is testing

SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 90
Large-scale testing (Phase 3)Looking for participantsNCT06855277
What this trial is testing

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 940
Testing effectiveness (Phase 2)Study completedNCT00450619
What this trial is testing

153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)Study completedNCT02125357
What this trial is testing

Sequencing Abiraterone and Enzalutamide in mCRPC

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
British Columbia Cancer Agency 202
Large-scale testing (Phase 3)Study completedNCT03016312
What this trial is testing

Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Hoffmann-La Roche 759
Testing effectiveness (Phase 2)Ended earlyNCT03741712
What this trial is testing

SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 9
Testing effectiveness (Phase 2)Study completedNCT01718353
What this trial is testing

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostate Cancer Metastatic
Sanofi 63
Not applicableStudy completedNCT07450157
What this trial is testing

Patient Characteristics, Treatment Patterns and Outcomes Among Patients Treated With 177Lu-PSMA-617

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 6,448
Early research (Phase 1)Study completedNCT03136640
What this trial is testing

ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Castration-resistant Prostate Cancer
Modra Pharmaceuticals 23
Testing effectiveness (Phase 2)Study completedNCT01748500
What this trial is testing

Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
University Health Network, Toronto 21
Testing effectiveness (Phase 2)Study completedNCT00411528
What this trial is testing

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Who this might be right for
Metastatic Hormone Refractory Prostate Cancer
Novartis Pharmaceuticals 185
Next Page